NZ604127A - Neuroendocrine tumor treatment using mtor inhibitors - Google Patents
Neuroendocrine tumor treatment using mtor inhibitorsInfo
- Publication number
- NZ604127A NZ604127A NZ604127A NZ60412706A NZ604127A NZ 604127 A NZ604127 A NZ 604127A NZ 604127 A NZ604127 A NZ 604127A NZ 60412706 A NZ60412706 A NZ 60412706A NZ 604127 A NZ604127 A NZ 604127A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mtor inhibitors
- tumor treatment
- neuroendocrine tumor
- tumours
- rapamycin
- Prior art date
Links
- 206010052399 Neuroendocrine tumour Diseases 0.000 title 1
- 229940124302 mTOR inhibitor Drugs 0.000 title 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 title 1
- 201000011519 neuroendocrine tumor Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009996 pancreatic endocrine effect Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ622710A NZ622710A (en) | 2005-11-21 | 2006-11-20 | Neuroendocrine tumor treatment using mtor inhibitors |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523658A GB0523658D0 (en) | 2005-11-21 | 2005-11-21 | Organic compounds |
GB0601082A GB0601082D0 (en) | 2006-01-19 | 2006-01-19 | Organic Compounds |
GB0602747A GB0602747D0 (en) | 2006-02-10 | 2006-02-10 | Organic compounds |
GB0607942A GB0607942D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
GB0609272A GB0609272D0 (en) | 2006-05-10 | 2006-05-10 | Organic compounds |
GB0609912A GB0609912D0 (en) | 2006-05-18 | 2006-05-18 | Organic compounds |
EP06120660 | 2006-09-14 | ||
NZ58716306 | 2006-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ604127A true NZ604127A (en) | 2014-05-30 |
Family
ID=58408253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ604127A NZ604127A (en) | 2005-11-21 | 2006-11-20 | Neuroendocrine tumor treatment using mtor inhibitors |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ604127A (en) |
-
2006
- 2006-11-20 NZ NZ604127A patent/NZ604127A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01964A (en) | ||
NO20082683L (en) | Neuroendocrine tumor therapy | |
CZ309247B6 (en) | 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour | |
MX2023008716A (en) | Camptothecin compound, preparation method therefor, and application thereof. | |
EP2395834A4 (en) | Sodium nitrite-containing pharmaceutical compositions | |
MX2007009649A (en) | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer. | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
MX2008012422A (en) | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors. | |
TW200738262A (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
WO2008124085A3 (en) | Methods of using combinations of mek and jak-2 inhibitors | |
HK1120441A1 (en) | Drugs for treatment of ovarian cancer | |
HK1140141A1 (en) | Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
MX2007004955A (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally. | |
MX2008011633A (en) | Aminoquinolones as gsk-3 inhibitors. | |
MX2013010770A (en) | Treatment of solid tumours. | |
WO2005117542A3 (en) | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments | |
EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
EP2061456A4 (en) | Compositions and methods for inhibiting cytochrome p450 | |
MX2008015775A (en) | Compounds and compositions for treatment of cancer. | |
TW200631606A (en) | Organic compounds | |
EA201071352A1 (en) | TRICYCLIC NITROGEN-CONTAINING COMPOUNDS AND THEIR APPLICATION AS BACTERICIDAL MEANS | |
MY158929A (en) | Pharmaceutical combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 20 NOV 2016 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20140909 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2017 BY CPA GLOBAL Effective date: 20161021 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2018 BY CPA GLOBAL Effective date: 20171019 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2019 BY CPA GLOBAL Effective date: 20181018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2020 BY CPA GLOBAL Effective date: 20191017 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2021 BY CPA GLOBAL Effective date: 20201022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2022 BY CPA GLOBAL Effective date: 20211022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2023 BY CPA GLOBAL Effective date: 20221020 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2024 BY CPA GLOBAL Effective date: 20231019 |